SCHEMBL25243401

SCHEMBL25243401

CC(C)(C)OC(=O)NCc1nn(-c2ccc(S(F)(F)(F)(F)F)cc2)c2ccccc12

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TEAD1 P28347 1/20 0.42
▸ TEAD4 Q15561 1/20 0.42
▸ TEAD2 Q15562 1/20 0.42
▸ TEAD3 Q99594 1/20 0.42
▸ HDAC10 Q969S8 1/20 0.42
▸ HDAC6 Q9UBN7 1/20 0.42
▸ BRD4 O60885 3/20 0.42
▸ NAMPT P43490 2/20 0.40
▸ CYP2D6 P10635 3/20 0.40
▸ CYP1A2 P05177 2/20 0.39
▸ SCN9A Q15858 2/20 0.39
▸ RARG P13631 1/20 0.39
▸ RORC P51449 1/20 0.39
▸ MEN1 O00255 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ KDM4A O75164 1/20 0.37
▸ BRD9 Q9H8M2 1/20 0.37
▸ BAZ2B Q9UIF8 1/20 0.37
▸ BAZ2A Q9UIF9 1/20 0.37
▸ L3MBTL1 Q9Y468 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30424238 1.00 TEAD1 (0.42) TEAD1TEAD4TEAD2TEAD3HDAC10
SCHEMBL25679235 0.86 TEAD1 (0.45) TEAD1TEAD4TEAD2TEAD3HDAC10
SCHEMBL30469093 0.86 TEAD1 (0.45) TEAD1TEAD4TEAD2TEAD3HDAC10
SCHEMBL25289583 0.86 TEAD1 (0.37) TEAD1TEAD4TEAD2TEAD3BRD4
SCHEMBL30424829 0.85 BRD4 (0.36) HDAC10HDAC6BRD4NAMPTCYP2D6
SCHEMBL25203706 0.85 BRD4 (0.36) HDAC10HDAC6BRD4NAMPTCYP2D6
SCHEMBL25747827 0.85 ABCB1 (0.46) TEAD1TEAD4TEAD2TEAD3HDAC10
SCHEMBL25231312 0.85 RORC (0.45) TEAD1TEAD4TEAD2TEAD3CYP2D6
SCHEMBL25247529 0.84 TEAD1 (0.60) TEAD1TEAD4TEAD2TEAD3HDAC10
SCHEMBL30424251 0.84 NSD2 (0.37) TEAD1TEAD4TEAD2TEAD3HDAC10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118302411-A Therapeutic indazole compounds and methods of use thereof for the treatment of cancer 基因泰克公司 2024-07-05 — — CN disclosed
US-20230202984-A1 THERAPEUTIC COMPOUNDS AND METHODS OF USE GENENTECH, INC. (US) 2023-06-29 — — US disclosed
US-20230202984-A1 THERAPEUTIC COMPOUNDS AND METHODS OF USE GENENTECH, INC. (US) 2023-06-29 — — US disclosed
US-20230202984-A1 THERAPEUTIC COMPOUNDS AND METHODS OF USE GENENTECH, INC. (US) 2023-06-29 — — US disclosed
WO-2023097195-A1 THERAPEUTIC INDAZOLE COMPOUNDS AND METHODS OF USE IN THE TREATMENT OF CANCER GENENTECH, INC. (US) 2023-06-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230202984-A1 THERAPEUTIC COMPOUNDS AND METHODS OF USE VHL, TP53, MCL1 TEAD1 282/4885TEAD4 162/4885TEAD2 129/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback